Persistent and paroxysmal atrial fibrillation appear to affect short- and long-term TAVR mortality rates in different ways, according to a new study of nearly 3,000 patients. Some trends fade over time, while others remain in place after many years.
A new paper from the National Bureau of Economic Research found the rise in care costs from mergers contributes to layoffs that have economic ripple effects.
The new data suggest that admitting patients for observation and additional imaging to monitor for delayed intracranial hemorrhage might often be unnecessary.
Teva Pharmaceuticals has officially launched generic liraglutide injections in the United States. Novo Nordisk currently sells liraglutide under the brand name Victoza.